Index RUT
P/E -
EPS (ttm) -0.39
Insider Own 35.92%
Shs Outstand 68.28M
Perf Week 3.86%
Market Cap 254.06M
Forward P/E -
EPS next Y -0.49
Insider Trans -0.77%
Shs Float 46.52M
Perf Month 24.56%
Income -38.77M
PEG -
EPS next Q -0.12
Inst Own 42.45%
Short Float 3.34%
Perf Quarter 29.63%
Sales 0.00M
P/S -
EPS this Y -60.00%
Inst Trans 40.24%
Short Ratio 6.47
Perf Half Y -5.41%
Book/sh 0.91
P/B 3.84
EPS next Y -5.17%
ROA -44.37%
Short Interest 1.55M
Perf Year 62.04%
Cash/sh 0.96
P/C 3.66
EPS next 5Y -
ROE -48.09%
52W Range 0.97 - 4.00
Perf YTD 161.19%
Dividend Est. -
P/FCF -
EPS past 5Y 27.24%
ROI -57.82%
52W High -12.50%
Beta 0.97
Dividend TTM -
Quick Ratio 10.68
Sales past 5Y 0.00%
Gross Margin -
52W Low 260.82%
ATR (14) 0.23
Dividend Ex-Date -
Current Ratio 10.68
EPS Y/Y TTM -23.77%
Oper. Margin 0.00%
RSI (14) 63.93
Volatility 8.92% 7.22%
Employees 25
Debt/Eq 0.02
Sales Y/Y TTM -
Profit Margin -
Recom 1.10
Target Price 8.90
Option/Short Yes / Yes
LT Debt/Eq 0.01
EPS Q/Q -68.78%
Payout -
Rel Volume 1.35
Prev Close 3.50
Sales Surprise -
EPS Surprise -10.50%
Sales Q/Q -
Earnings Aug 08 AMC
Avg Volume 240.00K
Price 3.50
SMA20 11.79%
SMA50 17.79%
SMA200 39.28%
Trades
Volume 275,595
Change 0.00%
Date
Action
Analyst
Rating Change
Price Target Change
Sep-09-24 Resumed
Leerink Partners
Outperform
$6 → $7
Aug-30-24 Initiated
Raymond James
Outperform
$9
Aug-30-24 Initiated
H.C. Wainwright
Buy
$6
Jun-13-24 Initiated
Rodman & Renshaw
Buy
$7
Apr-12-23 Initiated
B. Riley Securities
Buy
$6
Nov-22-22 Initiated
SVB Leerink
Outperform
$6
Jun-03-19 Initiated
SVB Leerink
Outperform
$14
Jun-03-19 Initiated
Stifel
Buy
$20
Jun-03-19 Initiated
Needham
Buy
$18
Jun-03-19 Initiated
BMO Capital Markets
Outperform
$15
Sep-04-24 04:05PM
Aug-30-24 09:33AM
Aug-28-24 07:30AM
Aug-08-24 09:58PM
04:05PM
07:30AM
Loading…
Aug-01-24 07:30AM
Jul-02-24 07:30AM
May-13-24 08:57AM
May-09-24 07:30AM
May-08-24 06:56AM
(Thomson Reuters StreetEvents) -8.97%
May-07-24 08:59PM
06:25PM
04:05PM
May-01-24 04:05PM
Apr-18-24 09:55AM
07:30AM
Loading…
Apr-09-24 07:30AM
Apr-04-24 08:30AM
07:30AM
Apr-02-24 07:30AM
Mar-21-24 10:46AM
Mar-20-24 08:53PM
05:33PM
04:05PM
Mar-13-24 04:05PM
Feb-28-24 07:30AM
Feb-06-24 07:30AM
Jan-17-24 12:00PM
Jan-04-24 07:30AM
Dec-05-23 07:30AM
Nov-30-23 09:35AM
09:55AM
Loading…
Nov-14-23 09:55AM
09:35AM
Nov-12-23 11:13AM
Nov-09-23 04:05PM
Nov-02-23 07:30AM
Nov-01-23 04:05PM
Oct-13-23 08:30AM
Oct-11-23 12:00PM
Sep-06-23 07:30AM
Aug-12-23 08:30AM
Aug-11-23 06:44AM
(Thomson Reuters StreetEvents)
Aug-10-23 04:05PM
Aug-03-23 04:05PM
Aug-01-23 07:30AM
Jul-06-23 07:30AM
Jun-04-23 10:45AM
May-30-23 07:30AM
May-22-23 04:05PM
(PR Newswire) -5.00%
+5.26%
May-16-23 11:46AM
May-12-23 06:38AM
(Thomson Reuters StreetEvents) -5.67%
May-11-23 04:05PM
May-10-23 08:48AM
May-09-23 07:30AM
May-04-23 04:05PM
May-02-23 07:30AM
Apr-27-23 07:30AM
Apr-11-23 04:05PM
Mar-18-23 02:03AM
Mar-17-23 06:19AM
(Thomson Reuters StreetEvents)
Mar-16-23 04:05PM
Mar-09-23 04:05PM
(PR Newswire) -9.22%
-14.21%
Mar-08-23 07:30AM
Mar-06-23 04:05PM
Feb-21-23 07:00AM
Feb-16-23 07:30AM
Feb-02-23 07:30AM
Jan-25-23 09:00AM
Jan-05-23 04:05PM
Dec-26-22 08:26AM
Dec-19-22 04:05PM
Nov-14-22 04:05PM
Nov-10-22 04:05PM
Nov-08-22 07:30AM
Nov-03-22 04:05PM
Oct-27-22 07:30AM
Sep-30-22 09:40AM
Sep-23-22 01:18AM
Sep-22-22 04:01PM
Sep-19-22 09:35AM
07:30AM
Sep-14-22 09:40AM
Sep-07-22 07:30AM
Aug-30-22 04:05PM
Aug-24-22 07:30AM
Aug-22-22 09:30AM
Aug-11-22 04:05PM
Aug-09-22 07:30AM
Aug-04-22 05:41PM
(PR Newswire) +5.22%
+7.71%
Jul-21-22 06:45AM
Jul-19-22 09:13AM
(Simply Wall St.) +14.33%
Jul-14-22 09:00AM
Jul-07-22 07:30AM
Jun-30-22 12:53PM
Jun-29-22 08:37AM
08:36AM
07:30AM
Jun-23-22 10:58AM
Jun-07-22 07:30AM
May-12-22 04:05PM
May-05-22 04:05PM
(PR Newswire) -5.66%
-7.20%
Trevi Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization Haduvio to treat serious neurologically mediated conditions. It includes treatment of chronic pruritus associated with prurigo nodularis and chronic cough in patients with idiopathic pulmonary fibrosis, and levodopa-induced dyskinesia in patients with Parkinson's disease. The company was founded by Thomas R. Sciascia and Jennifer L. Good in March 2011 and is headquartered in New Haven, CT.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
GOOD JENNIFER L President & CEO Sep 06 '24 Option Exercise 1.43 4,219 6,033 217,532 Sep 09 05:00 PM GOOD JENNIFER L President & CEO Sep 09 '24 Option Exercise 1.43 1,840 2,631 215,153 Sep 09 05:00 PM GOOD JENNIFER L President & CEO Sep 06 '24 Sale 3.03 4,219 12,784 213,313 Sep 09 05:00 PM GOOD JENNIFER L President & CEO Sep 09 '24 Sale 3.04 1,840 5,587 213,313 Sep 09 05:00 PM GOOD JENNIFER L President & CEO Sep 05 '24 Option Exercise 1.43 40,277 57,596 253,590 Sep 05 04:54 PM GOOD JENNIFER L President & CEO Sep 04 '24 Option Exercise 1.43 10,981 15,703 224,294 Sep 05 04:54 PM GOOD JENNIFER L President & CEO Sep 03 '24 Option Exercise 1.43 3,863 5,524 217,176 Sep 05 04:54 PM GOOD JENNIFER L President & CEO Sep 05 '24 Sale 3.11 40,277 125,310 213,313 Sep 05 04:54 PM GOOD JENNIFER L President & CEO Sep 04 '24 Sale 3.02 10,981 33,205 213,313 Sep 05 04:54 PM GOOD JENNIFER L President & CEO Sep 03 '24 Sale 3.02 3,863 11,677 213,313 Sep 05 04:54 PM GOOD JENNIFER L Officer Sep 03 '24 Proposed Sale 3.16 61,180 193,328 Sep 03 04:37 PM Meeker David P Director Aug 27 '24 Option Exercise 1.43 4,555 6,514 357,044 Aug 29 04:55 PM Meeker David P Director Aug 27 '24 Sale 2.93 4,555 13,353 352,489 Aug 29 04:55 PM Meeker David P Officer Aug 27 '24 Proposed Sale 2.98 4,555 13,573 Aug 27 04:10 PM SCIASCIA THOMAS Chief Scientific Officer Aug 19 '24 Option Exercise 1.43 16,496 23,589 236,811 Aug 21 04:00 PM SCIASCIA THOMAS Chief Scientific Officer Aug 19 '24 Sale 2.96 16,496 48,883 220,315 Aug 21 04:00 PM SCIASCIA THOMAS Chief Scientific Officer Aug 16 '24 Option Exercise 1.43 18,660 26,684 238,975 Aug 16 04:47 PM SCIASCIA THOMAS Chief Scientific Officer Aug 15 '24 Option Exercise 1.43 12,745 18,225 233,060 Aug 16 04:47 PM SCIASCIA THOMAS Chief Scientific Officer Aug 14 '24 Option Exercise 1.43 100 143 220,415 Aug 16 04:47 PM SCIASCIA THOMAS Chief Scientific Officer Aug 16 '24 Sale 2.76 18,660 51,440 220,315 Aug 16 04:47 PM SCIASCIA THOMAS Chief Scientific Officer Aug 15 '24 Sale 2.79 12,745 35,513 220,315 Aug 16 04:47 PM SCIASCIA THOMAS Chief Scientific Officer Aug 14 '24 Sale 2.75 100 275 220,315 Aug 16 04:47 PM SCIASCIA THOMAS Officer Aug 15 '24 Proposed Sale 2.61 48,001 125,282 Aug 15 04:23 PM SCIASCIA THOMAS Chief Scientific Officer May 29 '24 Option Exercise 2.19 59,354 129,985 267,801 May 31 04:07 PM SCIASCIA THOMAS Chief Scientific Officer May 29 '24 Sale 2.55 53,368 136,110 214,433 May 31 04:07 PM Delfini Lisa Chief Financial Officer May 22 '24 Option Exercise 0.51 16,043 8,198 57,629 May 24 04:12 PM Delfini Lisa Chief Financial Officer May 22 '24 Sale 2.64 4,350 11,485 53,279 May 24 04:12 PM GOOD JENNIFER L President & CEO May 20 '24 Option Exercise 2.19 25,037 54,831 238,350 May 22 04:30 PM GOOD JENNIFER L President & CEO May 20 '24 Sale 2.86 25,037 71,576 213,313 May 22 04:30 PM GOOD JENNIFER L President & CEO May 10 '24 Option Exercise 2.19 4,578 10,026 217,891 May 14 04:51 PM GOOD JENNIFER L President & CEO May 10 '24 Sale 2.90 4,578 13,276 213,313 May 14 04:51 PM Delfini Lisa Chief Financial Officer Oct 11 '23 Option Exercise 0.51 2,292 1,171 36,686 Oct 12 04:00 PM Delfini Lisa Chief Financial Officer Oct 11 '23 Sale 2.02 785 1,586 35,901 Oct 12 04:00 PM
Index RUT
P/E -
EPS (ttm) -4.37
Insider Own 10.76%
Shs Outstand 59.43M
Perf Week 6.69%
Market Cap 3.24B
Forward P/E -
EPS next Y -2.78
Insider Trans -3.42%
Shs Float 54.56M
Perf Month 16.66%
Income -260.72M
PEG -
EPS next Q -0.81
Inst Own 104.35%
Short Float 17.67%
Perf Quarter 26.44%
Sales 101.78M
P/S 31.80
EPS this Y -38.97%
Inst Trans 21.84%
Short Ratio 19.63
Perf Half Y 30.27%
Book/sh 0.64
P/B 82.21
EPS next Y 37.40%
ROA -75.00%
Short Interest 9.64M
Perf Year 120.31%
Cash/sh 5.22
P/C 10.14
EPS next 5Y -9.00%
ROE -234.10%
52W Range 20.97 - 55.64
Perf YTD 15.16%
Dividend Est. -
P/FCF -
EPS past 5Y -6.04%
ROI -89.54%
52W High -4.85%
Beta 2.07
Dividend TTM -
Quick Ratio 6.31
Sales past 5Y 175.40%
Gross Margin 88.01%
52W Low 152.46%
ATR (14) 2.27
Dividend Ex-Date -
Current Ratio 6.53
EPS Y/Y TTM -32.68%
Oper. Margin -260.93%
RSI (14) 62.64
Volatility 4.30% 4.70%
Employees 226
Debt/Eq 6.42
Sales Y/Y TTM 132.57%
Profit Margin -256.15%
Recom 1.20
Target Price 59.30
Option/Short Yes / Yes
LT Debt/Eq 6.40
EPS Q/Q 33.02%
Payout -
Rel Volume 0.56
Prev Close 54.55
Sales Surprise 1.00%
EPS Surprise 22.42%
Sales Q/Q 51.28%
Earnings Aug 06 BMO
Avg Volume 491.26K
Price 52.94
SMA20 8.40%
SMA50 10.14%
SMA200 21.71%
Trades
Volume 234,811
Change -2.95%
Date
Action
Analyst
Rating Change
Price Target Change
Sep-18-24 Initiated
H.C. Wainwright
Buy
$64
Sep-17-24 Initiated
JMP Securities
Mkt Outperform
$64
May-08-24 Downgrade
BofA Securities
Buy → Neutral
$49 → $42
Dec-19-23 Upgrade
Morgan Stanley
Equal-Weight → Overweight
$29 → $55
Aug-01-23 Upgrade
BofA Securities
Neutral → Buy
$22 → $27
Jan-18-23 Resumed
Canaccord Genuity
Buy
$52
Aug-08-22 Upgrade
Goldman
Neutral → Buy
$28
Aug-05-22 Upgrade
BofA Securities
Underperform → Neutral
$8 → $20
Jun-17-22 Reiterated
Needham
Buy
$40 → $25
Mar-02-22 Resumed
Stifel
Buy
$23
Feb-17-22 Upgrade
Ladenburg Thalmann
Neutral → Buy
$15
Dec-08-21 Initiated
Wells Fargo
Overweight
$30
Nov-19-21 Downgrade
Morgan Stanley
Overweight → Equal-Weight
$50 → $15
Sep-14-21 Resumed
Goldman
Neutral
$14
Aug-04-21 Downgrade
Ladenburg Thalmann
Buy → Neutral
Aug-04-21 Downgrade
BofA Securities
Neutral → Underperform
$33 → $17
Nov-30-20 Downgrade
BofA Securities
Buy → Neutral
$27 → $33
Jan-08-20 Initiated
Goldman
Sell
$18
Jul-12-19 Upgrade
Stifel
Hold → Buy
$34
Jul-08-19 Initiated
Canaccord Genuity
Buy
$35
Show Previous Ratings
Sep-18-24 10:46AM
Sep-16-24 04:01PM
Sep-10-24 01:55PM
(Investor's Business Daily)
Sep-06-24 01:31PM
(Investor's Business Daily)
Aug-26-24 08:02AM
08:00AM
Loading…
08:00AM
Aug-13-24 04:01PM
Aug-06-24 08:15AM
07:00AM
Jul-31-24 09:10AM
Jul-23-24 08:00AM
07:30AM
Jul-11-24 04:01PM
(GlobeNewswire) +5.00%
+7.34%
Jul-08-24 08:00AM
Jun-28-24 08:00AM
04:01PM
Loading…
Jun-11-24 04:01PM
Jun-03-24 04:02PM
08:02AM
May-22-24 04:00AM
May-09-24 04:01PM
May-08-24 10:51AM
03:06AM
May-07-24 10:34PM
(Thomson Reuters StreetEvents) -10.32%
02:52PM
08:58AM
08:36AM
08:15AM
07:00AM
May-06-24 08:00AM
Apr-30-24 10:01AM
06:30PM
Loading…
Apr-29-24 06:30PM
Apr-28-24 09:20AM
Apr-24-24 04:01PM
Apr-16-24 04:01PM
Apr-01-24 08:00AM
Mar-25-24 08:00AM
Mar-22-24 07:01PM
Mar-20-24 01:49AM
01:49AM
01:49AM
Mar-11-24 04:01PM
Mar-06-24 04:01PM
Feb-23-24 12:04PM
Feb-22-24 10:19PM
(Thomson Reuters StreetEvents) -9.73%
08:10AM
07:35AM
07:01AM
07:00AM
Feb-16-24 03:00AM
Feb-15-24 10:00AM
Feb-14-24 02:30AM
Feb-13-24 03:04PM
Feb-08-24 04:01PM
Feb-07-24 08:00AM
Jan-31-24 08:00AM
Jan-12-24 04:01PM
Jan-04-24 07:00AM
06:58AM
Dec-30-23 11:01AM
Dec-15-23 04:01PM
(GlobeNewswire) +9.92%
-5.11%
Dec-13-23 07:00AM
Dec-08-23 05:05AM
Dec-06-23 07:00AM
Nov-17-23 09:03AM
Nov-13-23 04:01PM
Nov-07-23 08:25AM
08:00AM
07:00AM
Nov-02-23 08:00AM
Nov-01-23 10:01AM
Oct-31-23 10:01AM
Oct-25-23 08:00AM
Oct-19-23 08:45AM
Oct-17-23 04:01PM
Oct-13-23 04:01PM
Oct-12-23 09:55AM
Oct-10-23 08:00AM
Sep-22-23 08:00AM
Sep-19-23 08:01AM
Sep-08-23 05:01PM
04:01PM
07:59AM
Sep-06-23 07:59AM
Aug-28-23 08:00AM
Aug-07-23 08:00AM
Aug-04-23 04:01PM
Aug-03-23 06:07AM
Aug-01-23 08:35AM
07:00AM
Jul-19-23 08:00AM
Jul-18-23 08:00AM
Jul-17-23 06:00AM
Jul-14-23 04:40PM
Jul-13-23 04:01PM
Jun-29-23 12:45PM
Jun-17-23 02:01PM
Jun-07-23 08:00AM
Jun-06-23 04:01PM
Jun-05-23 08:46AM
May-22-23 08:00AM
Rhythm Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company, which engages in the development and commercialization of therapeutics for patients with rare diseases. The firm offers IMCIVREE (setmelanotide), a precision medicine designed to treat hyperphagia and severe obesity caused by rare melanocortin-4 receptor (MC4R) diseases. It is also involved in the clinical development program for setmelanotide in other rare MC4R pathway diseases, as well as a preclinical suite of investigational candidates for the treatment of congenital hyperinsulinism. The company was founded by Bart Henderson in November 2008 and is headquartered in Boston, MA.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
GOOD JENNIFER L Director Sep 17 '24 Option Exercise 21.54 31,751 684,066 34,751 Sep 19 04:30 PM GOOD JENNIFER L Director Sep 17 '24 Sale 52.40 31,751 1,663,803 3,000 Sep 19 04:30 PM JENNIFER GOOD Director Sep 17 '24 Proposed Sale 49.52 31,751 1,572,310 Sep 17 04:42 PM Cramer Pamela J. Chief Human Resources Officer Sep 09 '24 Option Exercise 19.02 4,099 77,963 17,599 Sep 11 04:32 PM Cramer Pamela J. Chief Human Resources Officer Sep 09 '24 Sale 50.03 4,099 205,062 13,500 Sep 11 04:32 PM TETRAULT LYNN A. Director Sep 10 '24 Option Exercise 10.51 17,501 183,944 20,501 Sep 11 04:31 PM TETRAULT LYNN A. Director Sep 09 '24 Option Exercise 18.99 3,199 60,749 6,199 Sep 11 04:31 PM TETRAULT LYNN A. Director Sep 10 '24 Sale 49.65 17,501 868,923 3,000 Sep 11 04:31 PM TETRAULT LYNN A. Director Sep 09 '24 Sale 50.04 3,199 160,068 3,000 Sep 11 04:31 PM GOOD JENNIFER L Director Sep 09 '24 Option Exercise 13.34 37,241 496,706 40,241 Sep 11 04:30 PM GOOD JENNIFER L Director Sep 09 '24 Sale 50.45 37,241 1,878,700 3,000 Sep 11 04:30 PM LYNN TETRAULT393 COMMONWEALTH Director Sep 10 '24 Proposed Sale 50.66 17,501 886,601 Sep 10 04:22 PM JENNIFER GOOD Director Sep 09 '24 Proposed Sale 49.25 16,749 824,888 Sep 09 04:31 PM Cramer Pamela J. Chief Human Resources Officer Aug 26 '24 Option Exercise 19.02 3,200 60,864 16,700 Aug 28 04:31 PM Cramer Pamela J. Chief Human Resources Officer Aug 26 '24 Sale 50.01 3,200 160,018 13,500 Aug 28 04:31 PM TETRAULT LYNN A. Director Aug 26 '24 Option Exercise 18.99 4,300 81,657 7,300 Aug 28 04:31 PM TETRAULT LYNN A. Director Aug 26 '24 Sale 50.01 4,300 215,029 3,000 Aug 28 04:31 PM GOOD JENNIFER L Director Aug 26 '24 Option Exercise 18.63 14,508 270,322 17,508 Aug 28 04:30 PM GOOD JENNIFER L Director Aug 26 '24 Sale 50.01 14,508 725,526 3,000 Aug 28 04:30 PM JENNIFER GOOD Director Aug 26 '24 Proposed Sale 46.12 35,000 1,614,200 Aug 26 04:27 PM LYNN TETRAULT393 COMMONWEALTH Director Aug 26 '24 Proposed Sale 46.12 7,499 345,854 Aug 26 04:27 PM PAMELA CRAMER Officer Aug 26 '24 Proposed Sale 46.12 7,299 336,630 Aug 26 04:26 PM TETRAULT LYNN A. Director Aug 12 '24 Option Exercise 4.15 10,000 41,500 13,000 Aug 14 04:15 PM TETRAULT LYNN A. Director Aug 12 '24 Sale 44.65 10,000 446,462 3,000 Aug 14 04:15 PM Cramer Pamela J. Chief Human Resources Officer Aug 09 '24 Option Exercise 19.02 30,771 585,264 62,506 Aug 13 04:45 PM Cramer Pamela J. Chief Human Resources Officer Aug 09 '24 Sale 45.15 49,006 2,212,498 13,500 Aug 13 04:45 PM LYNN TETRAULT393 COMMONWEALTH Director Aug 12 '24 Proposed Sale 45.26 10,000 452,600 Aug 12 04:13 PM PAMELA CRAMER Officer Aug 09 '24 Proposed Sale 45.87 49,006 2,247,905 Aug 09 04:09 PM Cramer Pamela J. Chief Human Resources Officer Jul 29 '24 Sale 49.06 1,395 68,439 31,735 Jul 30 05:09 PM Shulman Joseph Chief Technical Officer Jul 16 '24 Option Exercise 27.35 10,468 286,300 10,498 Jul 18 05:59 PM Shulman Joseph Chief Technical Officer Jul 16 '24 Sale 53.00 10,468 554,817 30 Jul 18 05:59 PM Shulman Joseph Chief Technical Officer Jul 12 '24 Option Exercise 21.38 5,313 113,592 5,343 Jul 16 04:30 PM Shulman Joseph Chief Technical Officer Jul 12 '24 Sale 50.01 5,313 265,725 30 Jul 16 04:30 PM Shulman Joseph Chief Technical Officer May 09 '24 Option Exercise 6.80 3,984 27,091 4,014 May 13 04:21 PM Shulman Joseph Chief Technical Officer May 09 '24 Sale 38.47 3,984 153,259 30 May 13 04:21 PM German Christopher Paul Corporate Controller & CAO Apr 02 '24 Sale 41.76 368 15,368 795 Apr 03 08:00 PM Shulman Joseph Chief Technical Officer Mar 21 '24 Sale 40.34 18,235 735,600 30 Mar 22 04:55 PM Lee Jennifer Kayden EVP, Head of North America Mar 20 '24 Sale 38.77 18,235 707,005 6,852 Mar 22 04:16 PM Smith Hunter C Chief Financial Officer Mar 19 '24 Sale 39.22 15,515 608,498 97,939 Mar 19 08:57 PM Shulman Joseph Chief Technical Officer Mar 19 '24 Sale 39.22 15,515 608,498 18,265 Mar 19 08:56 PM Meeker David P President and CEO Mar 19 '24 Sale 39.22 45,494 1,784,275 174,605 Mar 19 08:54 PM Mazabraud Yann EVP, Head of International Mar 19 '24 Sale 39.22 16,000 627,520 24,495 Mar 19 08:53 PM Lee Jennifer Kayden EVP, Head of North America Mar 19 '24 Sale 39.22 15,515 608,498 25,087 Mar 19 08:52 PM Cramer Pamela J. Chief Human Resources Officer Mar 19 '24 Sale 39.22 15,515 608,498 30,005 Mar 19 08:50 PM Shulman Joseph Chief Technical Officer Feb 13 '24 Sale 50.00 1,865 93,250 1,119 Feb 15 06:14 PM Shulman Joseph Chief Technical Officer Feb 14 '24 Sale 50.01 1,089 54,461 30 Feb 15 06:14 PM Smith Hunter C Chief Financial Officer Feb 12 '24 Sale 51.38 1,209 62,118 80,413 Feb 13 08:50 PM Smith Hunter C Chief Financial Officer Feb 13 '24 Sale 49.82 709 35,322 79,704 Feb 13 08:50 PM Mazabraud Yann EVP, Head of International Feb 12 '24 Sale 51.38 1,594 81,900 7,702 Feb 13 08:49 PM Mazabraud Yann EVP, Head of International Feb 13 '24 Sale 49.84 957 47,697 6,745 Feb 13 08:49 PM Lee Jennifer Kayden EVP, Head of North America Feb 12 '24 Sale 51.38 1,023 52,562 7,467 Feb 13 08:47 PM Lee Jennifer Kayden EVP, Head of North America Feb 13 '24 Sale 49.83 615 30,645 6,852 Feb 13 08:47 PM Shulman Joseph Chief Technical Officer Feb 09 '24 Option Exercise 21.38 69,190 1,479,282 74,460 Feb 13 08:46 PM Shulman Joseph Chief Technical Officer Feb 09 '24 Sale 50.38 71,774 3,615,982 2,686 Feb 13 08:46 PM Shulman Joseph Chief Technical Officer Feb 12 '24 Sale 51.38 791 40,642 3,457 Feb 13 08:46 PM Shulman Joseph Chief Technical Officer Feb 13 '24 Sale 49.84 473 23,574 2,984 Feb 13 08:46 PM Cramer Pamela J. Chief Human Resources Officer Feb 12 '24 Sale 51.38 696 35,760 11,770 Feb 13 08:45 PM Lee Jennifer Kayden EVP, Head of North America Feb 01 '24 Sale 45.06 1,492 67,230 3,021 Feb 05 06:55 PM Smith Hunter C Chief Financial Officer Feb 01 '24 Sale 45.06 1,616 72,817 75,215 Feb 05 06:54 PM Shulman Joseph Chief Technical Officer Feb 01 '24 Sale 45.06 1,324 59,659 2,614 Feb 05 06:54 PM Meeker David P President and CEO Feb 01 '24 Sale 45.06 4,361 196,507 121,099 Feb 05 06:53 PM Cramer Pamela J. Chief Human Resources Officer Feb 01 '24 Sale 45.06 946 42,627 10,122 Feb 05 06:53 PM Shulman Joseph Chief Technical Officer Dec 28 '23 Option Exercise 21.38 6,800 145,384 7,926 Dec 29 04:30 PM Shulman Joseph Chief Technical Officer Dec 27 '23 Option Exercise 21.38 2,400 51,312 6,141 Dec 29 04:30 PM Shulman Joseph Chief Technical Officer Dec 28 '23 Sale 50.00 7,926 396,318 0 Dec 29 04:30 PM Shulman Joseph Chief Technical Officer Dec 27 '23 Sale 50.01 5,015 250,796 1,126 Dec 29 04:30 PM Smith Hunter C Chief Financial Officer Dec 06 '23 Option Exercise 6.88 20,000 137,600 81,406 Dec 07 04:16 PM Smith Hunter C Chief Financial Officer Dec 05 '23 Option Exercise 6.88 7,026 48,339 68,432 Dec 07 04:16 PM Smith Hunter C Chief Financial Officer Dec 06 '23 Sale 40.00 20,000 800,000 61,406 Dec 07 04:16 PM Smith Hunter C Chief Financial Officer Dec 05 '23 Sale 35.06 7,026 246,360 61,406 Dec 07 04:16 PM Smith Hunter C Chief Financial Officer Nov 24 '23 Option Exercise 6.88 10,974 75,501 72,380 Nov 28 04:05 PM Smith Hunter C Chief Financial Officer Nov 24 '23 Sale 35.02 10,974 384,336 61,406 Nov 28 04:05 PM Shulman Joseph Chief Technical Officer Nov 14 '23 Option Exercise 6.80 27,890 189,652 31,631 Nov 16 04:05 PM Shulman Joseph Chief Technical Officer Nov 14 '23 Sale 32.07 27,890 894,329 3,741 Nov 16 04:05 PM Lee Jennifer Kayden EVP, Head of North America Nov 14 '23 Option Exercise 6.80 12,030 81,804 13,677 Nov 16 04:05 PM Lee Jennifer Kayden EVP, Head of North America Nov 14 '23 Sale 32.01 13,677 437,819 0 Nov 16 04:05 PM Smith Hunter C Chief Financial Officer Nov 14 '23 Option Exercise 6.88 12,000 82,560 73,406 Nov 16 04:05 PM Smith Hunter C Chief Financial Officer Nov 14 '23 Sale 30.38 12,000 364,573 61,406 Nov 16 04:05 PM Lee Jennifer Kayden EVP, Head of North America Nov 08 '23 Option Exercise 6.80 5,712 38,842 7,359 Nov 13 05:44 PM Lee Jennifer Kayden EVP, Head of North America Nov 09 '23 Option Exercise 6.80 3,438 23,378 5,085 Nov 13 05:44 PM Lee Jennifer Kayden EVP, Head of North America Nov 08 '23 Sale 28.90 5,712 165,104 1,647 Nov 13 05:44 PM Lee Jennifer Kayden EVP, Head of North America Nov 09 '23 Sale 27.69 3,438 95,183 1,647 Nov 13 05:44 PM Lee Jennifer Kayden EVP, Head of North America Nov 03 '23 Option Exercise 6.80 80 544 1,727 Nov 07 06:17 PM Lee Jennifer Kayden EVP, Head of North America Nov 03 '23 Sale 28.00 80 2,240 1,647 Nov 07 06:17 PM
×
Upgrade your FINVIZ experience
Join thousands of traders who make more informed decisions with our premium features.
Real-time quotes, advanced visualizations, backtesting, and much more.
Learn more about FINVIZ*Elite